Ashley A Basiorka
Overview
Explore the profile of Ashley A Basiorka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, McGraw K, McLemore A, Komrokji R, Basiorka A, Al Ali N, et al.
Haematologica
. 2021 Jul;
107(3):737-739.
PMID: 34320786
No abstract available.
2.
Basiorka A, McGraw K, Abbas-Aghababazadeh F, McLemore A, Vincelette N, Ward G, et al.
Lancet Haematol
. 2018 Aug;
5(9):e393-e402.
PMID: 30072146
Background: NLRP3 inflammasome-directed pyroptotic cell death drives ineffective haemopoiesis in myelodysplastic syndromes. During inflammasome assembly, the apoptosis-associated speck-like protein containing a CARD (PYCARD, commonly known as ASC) adaptor protein polymerises...
3.
Cluzeau T, McGraw K, Irvine B, Masala E, Ades L, Basiorka A, et al.
Haematologica
. 2017 Oct;
102(12):2015-2020.
PMID: 28983059
Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β...
4.
Basiorka A, McGraw K, Eksioglu E, Chen X, Johnson J, Zhang L, et al.
Blood
. 2016 Oct;
128(25):2960-2975.
PMID: 27737891
Despite genetic heterogeneity, myelodysplastic syndromes (MDSs) share features of cytological dysplasia and ineffective hematopoiesis. We report that a hallmark of MDSs is activation of the NLRP3 inflammasome, which drives clonal...
5.
Sallman D, Cluzeau T, Basiorka A, List A
Front Oncol
. 2016 Jul;
6:151.
PMID: 27379212
Myelodysplastic syndromes (MDS) are characterized by bone marrow cytological dysplasia and ineffective hematopoiesis in the setting of recurrent somatic gene mutations and chromosomal abnormalities. The underlying pathogenic mechanisms that drive...
6.
Basiorka A, McGraw K, De Ceuninck L, Griner L, Zhang L, Clark J, et al.
Cancer Res
. 2016 May;
76(12):3531-40.
PMID: 27197154
In a subset of patients with non-del(5q) myelodysplastic syndrome (MDS), lenalidomide promotes erythroid lineage competence and effective erythropoiesis. To determine the mechanism by which lenalidomide promotes erythropoiesis, we investigated its...
7.
McGraw K, Cluzeau T, Sallman D, Basiorka A, Irvine B, Zhang L, et al.
Oncotarget
. 2015 Sep;
6(33):34437-45.
PMID: 26416416
P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of...
8.
McGraw K, Basiorka A, Johnson J, Clark J, Caceres G, Padron E, et al.
PLoS One
. 2014 Dec;
9(12):e114249.
PMID: 25469886
Anemia remains the principal management challenge for patients with lower risk Myelodysplastic Syndromes (MDS). Despite appropriate cytokine production and cellular receptor display, erythropoietin receptor (EpoR) signaling is impaired. We reported...
9.
Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris C, Gao J, et al.
Blood
. 2014 Jun;
124(5):780-90.
PMID: 24891322
The myelodysplastic syndromes (MDSs) include a spectrum of stem cell malignancies characterized by an increased risk of developing acute myeloid leukemia. Heterozygous loss of chromosome 5q (del[5q]) is the most...